Abstract
Neurodegenerative diseases such as Alzheimer's, Parkinson's and the transmissible spongiform encephalopathies (TSEs) are characterized by abnormal protein deposits, often with large amyloid fibrils. However, questions have arisen as to whether such fibrils or smaller subfibrillar oligomers are the prime causes of disease1,2. Abnormal deposits in TSEs are rich in PrPres, a protease-resistant form of the PrP protein with the ability to convert the normal, protease-sensitive form of the protein (PrPsen) into PrPres (ref. 3). TSEs can be transmitted between organisms by an enigmatic agent (prion) that contains PrPres (refs 4 and 5). To evaluate systematically the relationship between infectivity, converting activity and the size of various PrPres-containing aggregates, PrPres was partially disaggregated, fractionated by size and analysed by light scattering and non-denaturing gel electrophoresis. Our analyses revealed that with respect to PrP content, infectivity and converting activity peaked markedly in 17–27-nm (300–600 kDa) particles, whereas these activities were substantially lower in large fibrils and virtually absent in oligomers of ≤5 PrP molecules. These results suggest that non-fibrillar particles, with masses equivalent to 14–28 PrP molecules, are the most efficient initiators of TSE disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Caughey, B. & Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267–298 (2003)
Kayed, R. et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46363–46366 (2004)
Kocisko, D. A. et al. Cell-free formation of protease-resistant prion protein. Nature 370, 471–474 (1994)
Prusiner, S. B. Prions. Proc. Natl Acad. Sci. USA 95, 13363–13383 (1998)
Silveira, J. R., Caughey, B. & Baron, G. S. Prion protein and the molecular features of transmissible spongiform encephalopathy agents. Curr. Top. Microbiol. Immunol. 284, 1–50 (2004)
Caughey, B., Raymond, G. J., Kocisko, D. A. & Lansbury, P. T. Jr Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J. Virol. 71, 4107–4110 (1997)
Prusiner, S. B. Molecular biology of prion diseases. Science 252, 1515–1522 (1991)
Brown, P., Liberski, P. P., Wolff, A. & Gajdusek, D. C. Conservation of infectivity in purified fibrillary extracts of scrapie-infected hamster brain after sequential enzymatic digestion or polyacrylamide gel electrophoresis. Proc. Natl Acad. Sci. USA 87, 7240–7244 (1990)
Safar, J. et al. Molecular mass, biochemical composition, and physicochemical behaviour of the infectious form of the scrapie precursor protein monomer. Proc. Natl Acad. Sci. USA 87, 6373–6377 (1990)
Hope, J. The nature of the scrapie agent: the evolution of the virino. Ann. NY Acad. Sci. 724, 282–289 (1994)
Morillas, M., Vanik, D. L. & Surewicz, W. K. On the mechanism of α-helix to β-sheet transition in the recombinant prion protein. Biochemistry 40, 6982–6987 (2001)
Alper, T., Haig, D. A. & Clarke, M. C. The exceptionally small size of the scrapie agent. Biochem. Biophys. Res. Commun. 22, 278–284 (1966)
Gibbs, C. J. Jr, Gajdusek, D. C. & Latarjet, R. Unusual resistance to ionizing radiation of the viruses of kuru, Creutzfeldt-Jakob disease, and scrapie. Proc. Natl Acad. Sci. USA 75, 6268–6270 (1978)
Bellinger-Kawahara, C. G., Kempner, E., Groth, D., Gabizon, R. & Prusiner, S. B. Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. Virology 164, 537–541 (1988)
Gabizon, R., McKinley, M. P. & Prusiner, S. B. Purified prion proteins and scrapie infectivity copartition into liposomes. Proc. Natl Acad. Sci. USA 84, 4017–4021 (1987)
Raymond, G. J. et al. Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature 388, 285–288 (1997)
Prusiner, S. B. et al. Molecular properties, partial purification, and assay by incubation period measurements of the hamster scrapie agent. Biochemistry 19, 4883–4891 (1980)
Gast, K., et al. in Laser Light Scattering in Biochemistry (eds Harding, S. E., Sattelle, D. B. & Bloomfield, V. A.) 209–224 (The Royal Society of Chemistry, Cambridge, 1992)
Masel, J., Jansen, V. A. & Nowak, M. A. Quantifying the kinetic parameters of prion replication. Biophys. Chem. 77, 139–152 (1999)
Masel, J., Genoud, N. & Aguzzi, A. Efficient inhibition of prion replication by PrP-Fc2 suggests that the prion is a PrPSc oligomer. J. Mol. Biol. 345, 1243–1251 (2005)
Tzaban, S. et al. Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes. Biochemistry 41, 12868–12875 (2002)
Riesner, D. et al. Disruption of prion rods generates 10-nm spherical particles having high α-helical content and lacking scrapie infectivity. J. Virol. 70, 1714–1722 (1996)
Jeffrey, M. et al. Correlative light and electron microscopy studies of PrP localisation in 87V scrapie. Brain Res. 656, 329–343 (1994)
Raymond, G. J. & Chabry, J. in Techniques in Prion Research (eds Lehmann, S. & Grassi, J.) 16–26 (Birkhauser, Basel, 2004)
Wahlund, K.-G. in Field-Flow Fractionation Handbook (eds Schimpf, M., Caldwell, K. & Giddings, J. C.) 279–294 (John Wiley & Sons, New York, 2000)
Kocisko, D. A. et al. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol. 77, 10288–10294 (2003)
Maxson, L., Wong, C., Herrmann, L. M., Caughey, B. & Baron, G. S. A solid-phase assay for identification of modulators of prion protein interactions. Anal. Biochem. 323, 54–64 (2003)
Acknowledgements
We thank C. Y. Huang and D. Follmann (Biostatistics Research Branch, NIH/NIAID) for performing statistical analyses. We thank B. Chesebro, G. S. Baron and S. J. Robertson for critiquing the manuscript. This research was supported in part by the Intramural Research Program of the NIH/NIAID. V.L.S. acknowledges support from the Alberta Heritage Foundation for Medical Research through a clinical fellowship award. Author Contributions J.R.S. spearheaded the project, developed the critical methods and performed the PrPres disaggregation, fractionation and particle analyses. G.J.R. and A.G.H. purified PrPres and performed bioassays and other supporting experiments. R.E.R. provided bioassay standard curve data. V.L.S. and S.F.H. performed electron microscopy. B.C. helped with project design, data interpretation and writing (primarily with J.R.S.)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Reprints and permissions information is available at npg.nature.com/reprintsandpermissions. The authors declare no competing financial interests.
Supplementary information
Supplementary Notes
This file contains Supplementary Methods, Supplementary Discussion, additional references, and six Supplementary Figures. The file provides information about the selection of detergent conditions used in the study, details on the statistical analyses used to determine error bars, and additional data to support the conclusions derived from the figures in the main text. (DOC 1670 kb)
Rights and permissions
About this article
Cite this article
Silveira, J., Raymond, G., Hughson, A. et al. The most infectious prion protein particles. Nature 437, 257–261 (2005). https://doi.org/10.1038/nature03989
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nature03989
This article is cited by
-
Prion protein conversion at two distinct cellular sites precedes fibrillisation
Nature Communications (2023)
-
Propagation of PrPSc in mice reveals impact of aggregate composition on prion disease pathogenesis
Communications Biology (2023)
-
Extracellular vesicles with diagnostic and therapeutic potential for prion diseases
Cell and Tissue Research (2023)
-
Cell biology of prion strains in vivo and in vitro
Cell and Tissue Research (2023)
-
Therapeutic development of polymers for prion disease
Cell and Tissue Research (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.